Authors:
Einsele, H
Bertz, H
Beyer, J
Kiehl, MG
Runde, V
Kolb, HJ
Holler, E
Beck, R
Schwerdfeger, R
Schumacher, U
Hebart, H
Martin, H
Kienast, J
Ullmann, AJ
Maschmeyer, G
Kruger, W
Link, H
Schmidt, CA
Oettle, H
Klingebiel, T
Citation: H. Einsele et al., Reports of society meetings and consensus conferences, DEUT MED WO, 126(45), 2001, pp. 1278-1284
Authors:
Przybylski, GK
Oettle, H
Siegert, W
Schmidt, CA
Citation: Gk. Przybylski et al., Novel T-cell receptor delta gene rearrangement involving a recombining element located 2.6 kb 3 ' from the V delta 2 gene segment, LEUK RES, 25(12), 2001, pp. 1059-1065
Authors:
Rayes, N
Seehofer, D
Schmidt, CA
Oettle, H
Muller, AR
Steinmuller, T
Settmacher, U
Bechstein, WO
Neuhaus, P
Citation: N. Rayes et al., Prospective randomized trial to assess the value of preemptive oral therapy for CMV infection following liver transplantation., TRANSPLANT, 72(5), 2001, pp. 881-885
Authors:
Stroszczynski, C
Hosten, N
Puls, R
Nagel, S
Scholman, HJ
Wlodarczyk, W
Oettle, H
Moesta, KT
Schlag, PM
Felix, R
Citation: C. Stroszczynski et al., Histopathological correlation to MRI findings during and after laser-induced thermotherapy in a pig pancreas model, INV RADIOL, 36(7), 2001, pp. 413-421
Authors:
Oettle, H
Arnold, D
Esser, M
Huhn, D
Riess, H
Citation: H. Oettle et al., Paclitaxel as weekly second-line therapy in patients with advanced pancreatic carcinoma, ANTI-CANC D, 11(8), 2000, pp. 635-638
Citation: H. Oettle et al., The role of gemcitabine alone and in combination in the treatment of pancreatic cancer, ANTI-CANC D, 11(10), 2000, pp. 771-786
Authors:
Oettle, H
Arning, M
Pelzer, U
Arnold, D
Stroszczynski, C
Langrehr, J
Reitzig, P
Kindler, M
Herrenberger, J
Musch, R
Korsten, FW
Huhn, D
Riess, H
Citation: H. Oettle et al., A phase II trial of gemcitabine in combination with 5-fluorouracil (24-hour) and folinic acid in patients with chemonaive advanced pancreatic cancer, ANN ONCOL, 11(10), 2000, pp. 1267-1272
Authors:
Oettle, H
Meyer, L
Bechstein, WO
Riess, H
Citation: H. Oettle et al., 5-fluorouracil: Synchronous application of continuous and bolus therapy inheavily pretreated metastatic colorectal cancer: A phase I/II study, ONKOLOGIE, 23(2), 2000, pp. 128-132
Authors:
Oettle, H
Pelzer, U
Hochmuth, K
Diebold, T
Langrehr, J
Schmidt, CA
Arning, M
Vogl, TJ
Neuhaus, P
Huhn, D
Riess, H
Citation: H. Oettle et al., Phase I trial of gemcitabine (Gemzar (R), 24 h infusion 5-fluorouracil andfolinic acid in patients with inoperable pancreatic cancer, ANTI-CANC D, 10(8), 1999, pp. 699-704
Authors:
Binder, T
Siegert, W
Kruse, A
Oettle, H
Wilborn, F
Peng, RQ
Timm, H
Neuhaus, P
Schmidt, CA
Citation: T. Binder et al., Identification of human cytomegalovirus variants by analysis of single strand conformation polymorphism and DNA sequencing of the envelope glycoprotein B gene region-distribution frequency in liver transplant recipients, J VIROL MET, 78(1-2), 1999, pp. 153-162
Authors:
Sinzger, C
Bissinger, AL
Viebahn, R
Oettle, H
Radke, C
Schmidt, CA
Jahn, G
Citation: C. Sinzger et al., Hepatocytes are permissive for human cytomegalovirus infection in human liver cell culture and in vivo, J INFEC DIS, 180(4), 1999, pp. 976-986
Citation: S. Serke et al., Elevated reticulocyte count - a clue to the diagnosis of haemolytic-uraemic syndrome (HUS) associated with gemcitabine therapy for metastatic duodenal papillary carcinoma: a case report, BR J CANC, 79(9-10), 1999, pp. 1519-1521